| Literature DB >> 35664100 |
Abstract
Purpose: In this study, we empirically investigate the impact of the COVID-19 pandemic on China's stock price volatility during and after its initial outbreak, using time-series daily data covering the period from July to October, 2020 and 2021, respectively. Design/Methodology/Approach: In the estimation, the ARDL bounds test approach was employed to examine the existence of co-integration and the relationship of long-run and short-run between the new infection rates and stock price volatility, as stable and unstable variables are mixed. The inner-day and inter-day volatility, based on the Shanghai (securities) composite index, are estimated in separate empirical models. In addition, the Inter-bank overnight lending rate (IBOLR) is controlled in order to consider the effect of liquidity and investment cost. Findings and Implications: We find that in the initial year (2020) of the epidemic, the new infection rate is negatively correlated to stock prices in the short-term, whereas no significant evidence existed in the long-term, regardless of model specifications. However, after the epidemic's outbreak (2021), the result depicts that new infections increased stock prices in the long-term, and depressed its inner-day volatility in the short-term, which is inconsistent with most investigations. This phenomenon may be due to the fact that investors were more concerned about the withdrawal of monetary easing and fiscal stimulus, which were introduced to fight against the epidemic's impact on economy, than the epidemic itself. This study complements the limitations of most existing studies, which just focus on the period of the epidemic's outbreak, and provides insight into macroeconomic policy making in the era of the post COVID-19 epidemic such as the structural and ordered exit of the stimulating policies, intervention in IBOLR and balance social and economic sustainability.Entities:
Keywords: ARDL bounds test; COVID-19; IBOLR; policy withdraw; stock volatility
Mesh:
Year: 2022 PMID: 35664100 PMCID: PMC9159152 DOI: 10.3389/fpubh.2022.810102
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Summary statistics of main variables.
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
| CNIFa | 0.05 | 0.02 | 0.16 | 0.01 | 0.04 | 50 |
| INEDVa | 0.53 | 0.52 | 1 | 0.09 | 0.22 | 50 |
| INTDVa | 0.64 | 0.64 | 1 | 0.18 | 0.13 | 50 |
| INCRa | 0.53 | 0.53 | 1 | 0.02 | 0.17 | 50 |
| IBOLRa | 1.87 | 1.94 | 2.40 | 0.68 | 0.35 | 50 |
| CNIFb | 0.036 | 0.03 | 0.09 | 0.01 | 0.02 | 47 |
| INEDVb | 0.59 | 0.59 | 1 | 0.10 | 0.18 | 47 |
| INTDVb | 0.67 | 0.67 | 1 | 0.37 | 0.09 | 47 |
| INCRb | 0.60 | 0.62 | 1 | 0.10 | 0.19 | 47 |
| IBOLRb | 2.07 | 2.12 | 2.35 | 1.57 | 0.20 | 47 |
1. CNIFa, INEDVa, INTDVa, INCRa, IBOLRa denote new infection rate, inner-day volatility of stock index, inter-day volatility of the stock index, increase rate of the stock index, and the inter-bank overnight lending rate in 2020, respectively; while CNIFa, INEDVa, INTDVa, INCRa, IBOLRa denote the variables in 2021.
2. Variables of INEDVa, INTDVa, INCRa, INEDVb, INTDVb, INCRb are featured scaled.
Results of unite root tests.
|
|
|
|
| ||
|---|---|---|---|---|---|
|
|
| ||||
|
| |||||
| LnCNIRa | Intercept | −0.94 [0.77] | −7.15*** [0.00] | −1.28 [0.63] | −10.66 [0.00] |
| Trend and intercept | −1.50 [0.82] | −5.49*** [0.00] | −3.02 [0.14] | −10.50 [0.00] | |
| None | 0.79 [0.88] | −7.07*** [0.00] | 0.58 [0.84] | −10.51 [0.00] | |
| LnINCRa | Intercept | −6.92*** [0.00] | −11.31*** [0.00] | −6.94*** [0.00] | −49.90*** [0.00] |
| Trend and intercept | −6.98*** [0.00] | −11.18*** [0.00] | −7.01*** [0.00] | −45.09*** [0.00] | |
| None | −2.04** [0.04] | −11.43*** [0.00] | −3.06*** [0.00] | −48.84*** [0.00] | |
| LnINEDVa | Intercept | −4.99*** [0.00] | −8.61*** [0.00] | −4.94*** [0.00] | −17.58*** [0.00] |
| Trend and intercept | −4.95*** [0.00] | −8.52*** [0.00] | −4.90*** [0.00] | −17.35*** [0.00] | |
| None | −1.98** [0.05] | −8.70*** [0.00] | −2.36** [0.05] | −17.94*** [0.00] | |
| LnINTDVa | Intercept | −8.21*** [0.00] | −8.24*** [0.00] | −8.23*** [0.00] | −40.22*** [0.00] |
| Trend and intercept | −8.23***[0.00] | −8.17*** [0.00] | −8.27*** [0.00] | −40.05*** [0.00] | |
| None | −1.40*** [0.15] | −8.33*** [0.00] | −2.18*** [0.03] | −40.17*** [0.00] | |
| LnIBOLRa | Intercept | −4.29*** [0.00] | −6.63*** [0.00] | −3.92*** [0.00] | −10.93*** [0.00] |
| Trend and intercept | −4.26*** [0.00] | −6.56*** [0.00] | −3.81** [0.02] | −10.68*** [0.00] | |
| None | −1.00 [0.28] | −6.70*** [0.00] | −0.56 [0.47] | −11.15*** [0.00] | |
|
| |||||
| LnCNIRb | Intercept | −2.25 [0.19] | −9.54*** [0.00] | −2.20 [0.21] | −9.54*** [0.00] |
| Trend and intercept | −2.86 [0.18] | −9.46*** [0.00] | −2.88 [0.18] | −9.46*** [0.00] | |
| None | −1.25 [0.19] | −9.63*** [0.00] | −1.10 [0.24] | −9.62*** [0.00] | |
| LnINCRb | Intercept | −6.26*** [0.00] | −10.94*** [0.00] | −6.27*** [0.00] | −26.71*** [0.00] |
| Trend and intercept | −6.39*** [0.00] | −5.91*** [0.00] | −6.38*** [0.00] | −26.16*** [0.00] | |
| None | −1.14 [0.23] | −11.07*** [0.00] | −1.54 [0.11] | −26.94*** [0.00] | |
| LnINEDVb | Intercept | −5.53*** [0.00] | −9.50*** [0.00] | −5.51*** [0.00] | −20.74*** [0.00] |
| Trend and intercept | −5.51*** [0.00] | −9.40*** [0.00] | −5.46*** [0.00] | −20.94*** [0.00] | |
| None | −2.49** [0.01] | −9.61*** [0.00] | −2.28** [0.02] | −21.00*** [0.00] | |
| LnINTDVb | Intercept | −7.95*** [0.00] | −12.94*** [0.00] | −8.16*** [0.00] | −46.55*** [0.00] |
| Trend and intercept | −7.87*** [0.00] | −12.80*** [0.00] | −8.19*** [0.00] | −46.54*** [0.00] | |
| None | −1.33 [0.17] | −13.09*** [0.00] | −1.98** [0.05] | −45.70*** [0.00] | |
| LnIBOLRb | Intercept | −4.42*** [0.00] | −9.39*** [0.00] | −4.42*** [0.00] | −12.64*** [0.00] |
| Trend and intercept | −4.35*** [0.00] | −9.31*** [0.00] | −4.35*** [0.00] | −12.61*** [0.00] | |
| None | −0.78 [0.37] | −9.47*** [0.00] | −0.78 [0.37] | −12.77*** [0.00] | |
1. CNIFa, INEDVa, INTDVa, INCRa, IBOLRa denote new infection rate, inner-day volatility of the stock index, inter-day volatility of the stock index, increase rate of the stock index, and the inter-bank overnight lending rate in 2020, respectively; while CNIFa, INEDVa, INTDVa, INCRa, IBOLRa denote the variables in 2021. 2. p-values are provided in brackets. 3. (***), (**), (*) significant at 1, 5, 10% levels, respectively.
Optimal lags of models.
|
|
|
|
|---|---|---|
|
| ||
| A1 | 0.96 (2) | 1.77 (1) |
| A2 | 1.67 (3) | 2.37 (1) |
| A3 | 2.57 (2) | 1.23 (1) |
|
| ||
| B1 | −7.13 (1) | −6.63 (1) |
| B2 | −6.55 (1) | −6.10 (1) |
| B3 | −7.86 (1) | −7.36 (1) |
The optimal number of lags is provided in parentheses.
Results of ARDL bounds test.
|
|
|
|
|---|---|---|
|
| ||
| A1 | 22.53 | 22.08 |
| A2 | 13.72 | 13.72 |
| A3 | 25.06 | 25.06 |
|
| ||
| B1 | 14.20 | 14.20 |
| B2 | 12.69 | 12.69 |
| B3 | 19.54 | 19.54 |
|
| ||
|
|
|
|
|
|
|
|
| 1% | 6.36 | 5.15 |
| 5% | 4.85 | 3.79 |
| 10% | 4.14 | 3.17 |
is significant at 1% significance level.
Empirical results in long run and short run.
|
|
|
|
|
|---|---|---|---|
|
| |||
|
| |||
| C | −0.68*** (−3.13) | −0.72*** (−2.66) | −0.36*** (−3.00) |
| CNIF | 0.57 (0.35) | 1.85 (0.92) | 0.01 (0.01) |
| IBOLR | −0.17 (−0.55) | −0.23 (−0.60) | −0.22 (−0.13) |
|
| |||
| c | −0.01 (−0.23) | −0.00 (−0.08) | −0.03 (−1.14) |
| Δ CNIF | −5.17* (−1.64) | −3.67 (−1.06) | −0.18 (−0.10) |
| Δ IBOLR | −0.49** (−2.32) | −0.50** (−2.22) | −0.18 (−1.57) |
|
|
|
|
|
|
| |||
|
| |||
| C | −0.68** (−2.06) | −0.27 (−0.48) | −1.03*** (−3.58) |
| CNIF | 1.78* (1.86) | 2.68 (1.60) | 0.39 (0.58) |
| IBOLR | −0.10 (−0.23) | −0.83 (−1.11) | 0.73* (1.92) |
|
| |||
| c | 0.00 (0.02) | −0.01 | 0.00 (0.09) |
| Δ CNIF | 1.24 (0.62) | −7.57** (−2.59) | −2.33 (−1.43) |
| Δ IBOLR | 0.01 (0.04) | −1.19** (−2.60) | 0.71*** (2.85) |
1. CNIFa, INEDVa, INTDVa, INCRa, IBOLRa denote new infection rates, inner-day volatility of the stock index, inter-day volatility of the stock index, increase rate of the stock index, and the inter-bank overnight lending rate in 2020, respectively; while CNIFa, INEDVa, INTDVa, INCRa, IBOLRa denote variables in 2021.
2. t-values are provided in parentheses.
3. (***), (**), (*) significant at 1, 5, 10% levels, respectively.